1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery...
-
Upload
clarence-mcdaniel -
Category
Documents
-
view
220 -
download
0
Transcript of 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery...
![Page 1: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/1.jpg)
1
Edwards SAPIEN Transcatheter Heart Valve Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Model 9000TFX and RetroFlex 3 and Ascendra
Delivery SystemsDelivery Systems
FDA Review of P110021FDA Review of P110021
Lisa KennellLisa Kennell
Division of Cardiovascular DevicesDivision of Cardiovascular DevicesOffice of Device EvaluationOffice of Device Evaluation
Food and Drug AdministrationFood and Drug Administration
Circulatory System Devices Panel MeetingCirculatory System Devices Panel MeetingJune 13, 2012June 13, 2012
![Page 2: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/2.jpg)
2
FDA Team PresentersFDA Team Presenters
Lisa KennellLisa KennellIntroduction and Pre-ClinicalIntroduction and Pre-Clinical
Xiting (Cindy) Yang, PhDXiting (Cindy) Yang, PhDStatistical SummaryStatistical Summary
Julie Swain, MDJulie Swain, MDClinical SummaryClinical Summary
Veronica Sansing, PhDVeronica Sansing, PhDPost-Approval StudyPost-Approval Study
Sonna Patel-Raman, PhDSonna Patel-Raman, PhDSummarySummary
![Page 3: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/3.jpg)
3
OutlineOutline
• Regulatory HistoryRegulatory History• Proposed Indications for useProposed Indications for use• Device DescriptionDevice Description• Pre-Clinical TestingPre-Clinical Testing• Overview of PARTNER studyOverview of PARTNER study• Statistical ReviewStatistical Review• Clinical ReviewClinical Review• Post-Approval StudyPost-Approval Study• FDA SummaryFDA Summary
![Page 4: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/4.jpg)
4
• SAPIEN IDE Study G030069SAPIEN IDE Study G030069– Pivotal PARTNER study began in 2007Pivotal PARTNER study began in 2007
• Premarket Approval (PMA) Application Premarket Approval (PMA) Application – PMA application received May 2, 2011PMA application received May 2, 2011– Amended February 17, 2012Amended February 17, 2012– Data “freeze” or “lock” date September 21, 2011Data “freeze” or “lock” date September 21, 2011
• Ongoing Study (Continued Access)Ongoing Study (Continued Access)– Currently approved for 1984 patients at 23 sitesCurrently approved for 1984 patients at 23 sites
Regulatory HistoryRegulatory History
![Page 5: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/5.jpg)
5
Proposed Indications for UseProposed Indications for Use
The Edwards SAPIEN Transcatheter Heart Valve The Edwards SAPIEN Transcatheter Heart Valve (THV) is indicated for use in the following clinical (THV) is indicated for use in the following clinical conditions:conditions:
TransfemoralTransfemoral
For use in patients with severe symptomatic native aortic For use in patients with severe symptomatic native aortic valve stenosis who have been examined by a heart team valve stenosis who have been examined by a heart team including a cardiac surgeon and found to be:including a cardiac surgeon and found to be:• inoperable and in whom existing co-morbidities would not inoperable and in whom existing co-morbidities would not
preclude the expected benefit from correction of the aortic preclude the expected benefit from correction of the aortic stenosis, orstenosis, or
• operable candidates for aortic valve replacement but who operable candidates for aortic valve replacement but who are at a greater than or equal to 15% (high) risk of are at a greater than or equal to 15% (high) risk of mortality for surgical aortic valve replacement.mortality for surgical aortic valve replacement.
![Page 6: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/6.jpg)
6
Proposed Indications for Use Proposed Indications for Use (continued)(continued)
Transapical
For use in patients with severe symptomatic native aortic valve stenosis who have been examined by a heart team including a cardiac surgeon and found to be operative candidates for aortic valve replacement but who are at a greater than or equal to 15% (high) risk of mortality for surgical aortic valve replacement.
![Page 7: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/7.jpg)
7
Device DescriptionDevice Description
• The Edwards SAPIEN THVThe Edwards SAPIEN THV – Heterologous (bovine) tissue sutured within a stainless steel stentHeterologous (bovine) tissue sutured within a stainless steel stent– Aortic Sizes: 23 and 26 mmAortic Sizes: 23 and 26 mm– Polyethylene terephthalate (PET) cuffPolyethylene terephthalate (PET) cuff
• RetroFlex 3 or RetroFlex delivery system RetroFlex 3 or RetroFlex delivery system available in sizes 20 and 23 mm for pre-dilating to ease crossing size 23 and 26 mm valve (transfemoral applications)
• Ascendra Balloon Aortic Valvuloplasty and Balloon Catheters for pre-dilating and delivering the valve (transapical applications)
• Sheath Set with Introducer, Sheath, and Loader with Cap• A dilator kit
![Page 8: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/8.jpg)
8
FDA Pre-Clinical Review TeamFDA Pre-Clinical Review Team
• Co-Team LeadersCo-Team Leaders– Lisa KennellLisa Kennell– Changfu Wu, PhDChangfu Wu, PhD
• EngineeringEngineering– Changfu Wu, PhDChangfu Wu, PhD– Nandini Duraiswamy, PhDNandini Duraiswamy, PhD– Sandy Stewart, PhDSandy Stewart, PhD– Stephen Retta, MSStephen Retta, MS– Albert Rodriguez, BSAlbert Rodriguez, BS
• Animal StudyAnimal Study– Michael John, MPHMichael John, MPH
• Patient Labeling ReviewPatient Labeling Review– David Windt, MPHDavid Windt, MPH
• MRIMRI– Terry Woods, PhDTerry Woods, PhD– Wolfgang Kainz, PhDWolfgang Kainz, PhD
• MicrobiologyMicrobiology – Lisa Kennell, BSLisa Kennell, BS
• Bio-Research Bio-Research MonitoringMonitoring
– Adam Donat, MSAdam Donat, MS
• Manufacturing Manufacturing – Andrea Artman, MSAndrea Artman, MS
![Page 9: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/9.jpg)
9
Pre-Clinical TestingPre-Clinical Testing• BiocompatibilityBiocompatibility• Sterility & PackagingSterility & Packaging• Magnetic Resonance Imaging Magnetic Resonance Imaging
(MRI)(MRI)• Delivery systemDelivery system• ManufacturingManufacturing• Bio-research monitoringBio-research monitoring
• Corrosion resistance Corrosion resistance evaluation of the valve stentevaluation of the valve stent
• Fatigue evaluation of the valve Fatigue evaluation of the valve stentstent
• Hydrodynamic and durability Hydrodynamic and durability testing of the whole valvetesting of the whole valve
• Valve migration potential Valve migration potential evaluationevaluation
• In VivoIn Vivo sheep studies sheep studies
Most testing done as part of P100041 for inoperable PMA; only Most testing done as part of P100041 for inoperable PMA; only Ascendra accessories were new in this PMA. No further Ascendra accessories were new in this PMA. No further concerns about the majority of testing.concerns about the majority of testing.
However, no testing was conducted on However, no testing was conducted on valve-valve-in-valvein-valve implantation. implantation.
![Page 10: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/10.jpg)
10
Valve-in-Valve
• At least 2 cases of valve-in-valve in Cohort A study
• Many more cases outside of the U.S., as reported in the literature
• Different valve positions– Aortic, mitral, tricuspid, and pulmonic
• Different configurations– TAV-in-TAV– TAV-in-SAV– TAV-in-Ring
![Page 11: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/11.jpg)
11
Valve-in-Valve: Potential Risks
• Size mismatch – 2 sizes for SAPEN THV vs. various sizes for
surgically placed bioprosthetic valves– Impact on stable anchoring and uncompromised
hemodynamic performance
• Valve migration/embolization• Long term durability• Fretting fatigue• Galvanic corrosion• Access to the coronary ostia
![Page 12: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/12.jpg)
12
PARTNERIDE Trial
Cohort A(High Risk)
Cohort B(Inoperable)
OpenAVR*
SAPIEN(TA & TF)
ControlSAPIEN(TF only)
Open AVR refers to median sternotomy, partial sternotomy or limited thoracotomy (i.e., minimally invasive approach)
![Page 13: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/13.jpg)
13
Study Endpoints
• Primary endpoint was all cause mortality at 1 year in the Intent-To-Treat population
• FDA will focus mainly on totality of the data/clinically important endpoints
![Page 14: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/14.jpg)
14
FDA Clinically Important Secondary Endpoints
• Death• Neurological Events• Aortic Regurgitation• Bleeding• Vascular Complications• Atrial Fibrillation
![Page 15: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/15.jpg)
15
Secondary Endpoints Chosen by Sponsor for Labeling Purposes
• Time from randomization to the first occurrence of MACCE within 1 year– Death– MI– Stroke– Renal Failure
• Total hospital days from the index procedure to one year post procedure
• NYHA at 1 year• Six minute walk test at 1 year
![Page 16: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/16.jpg)
16
Other Analyses
• Primary endpoint in transapical and transfemoral groups separately
• Gender differences for primary endpoint
![Page 17: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/17.jpg)
17
FDA Statistical Review of P110021FDA Statistical Review of P110021
Xiting Yang, Ph.D.Xiting Yang, Ph.D.
Cardiovascular and Ophthalmic Devices BranchCardiovascular and Ophthalmic Devices BranchDivision of BiostatisticsDivision of Biostatistics
Office of Surveillance and BiometricsOffice of Surveillance and Biometrics
![Page 18: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/18.jpg)
18
1. Study Design1. Study Design
2. Patient Accountability2. Patient Accountability
3. Primary Endpoint Results3. Primary Endpoint Results
4. Sponsor Secondary Endpoint Results4. Sponsor Secondary Endpoint Results
5. Summary5. Summary
OutlineOutline
![Page 19: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/19.jpg)
19
Study DesignStudy Design
• Prospective, non-blinded, randomized, controlled, multi-center clinical trial
• Sample size ranges 690 to 750
• Transfemoral: minimum 450
• Transapical: minimum 200
• Assume 65% patients in Transfemoral approach
Transfemoral Access
Transfemoral (TF)(n=492)
Transapical (TA)(n=207)
1:1 Randomization 1:1 Randomization
TF SAPIEN(n=244)
AVR (Control)(n=248)
TA SAPIEN(n=104)
AVR (Control)(n=103)
Yes No
Transfemoral Access
Transfemoral (TF)(n=492)
Transapical (TA)(n=207)
1:1 Randomization 1:1 Randomization
TF SAPIEN(n=244)
AVR (Control)(n=248)
TA SAPIEN(n=104)
AVR (Control)(n=103)
Yes No
![Page 20: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/20.jpg)
20
Patient Accountability
Control: AVR (n= 351)• 5 died prior to the procedure• 5 deteriorated prior to the procedure• 28 either refused AVR or withdrew• 1 patient started with AVR and converted to SAPIEN
SAPIEN: TAVR (n= 348)• 2 died prior to the procedure• 1 deteriorated prior to the procedure • 1 refused SAPIEN • 11 patients started with SAPIEN but converted to AVR
![Page 21: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/21.jpg)
21
Analysis PopulationsAnalysis Populations
• Intent-To-Treat (ITT) – All randomized patients
• “As Treated” (AT)– AT AVR: patients randomized to the AVR arm for
whom the valve implant procedure has begun.– AT SAPIEN: patients randomized to the treatment
arm for whom the study valve implant procedure has begun.
![Page 22: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/22.jpg)
22
Primary Safety and Effectiveness EndpointPrimary Safety and Effectiveness Endpoint
![Page 23: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/23.jpg)
23
Primary Safety and Effectiveness Endpoint (ITT)Primary Safety and Effectiveness Endpoint (ITT)
•The upper bound of the one-sided 95% C.I. of mortality difference for (SAPIEN -AVR) is 3.0%•p-value (non-inferiority, 7.5% margin): 0.001
![Page 24: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/24.jpg)
24
Missing Data and Worst Case Missing Data and Worst Case Analysis (ITT)Analysis (ITT)
• Missing data- unknown status at 1 year– 26 patients in AVR– 4 patients in SAPIEN
• Worst Case Analysis Assumptions– Missing patients in AVR are counted as alive
(success) and those in SAPIEN as dead (failure)
• Non-inferiority endpoint is still met (7.5% margin)
• Does NOT address– SAPIEN patients receiving AVR– AVR patients undergoing concomitant operations
![Page 25: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/25.jpg)
25
Gender Analysis (ITT)• Male/Female Composition
– Males compose 56.7% (198/351) of AVR arm – Males compose 57.8% (201/348) of SAPIEN arm
• Significant Interaction (p-value < 0.10)Significant Interaction (p-value < 0.10)• Primary Endpoint by Gender
• Nonrandomized Continued Access Protocol CohortNonrandomized Continued Access Protocol Cohort– 770/1588 (48.5%) female770/1588 (48.5%) female
– Female mortality rate (K-M estimated): 18.5%Female mortality rate (K-M estimated): 18.5%
– Male mortality rate (K-M estimated): 25.9%Male mortality rate (K-M estimated): 25.9%
Gender Control (AVR) SAPIEN (TAVR) 95% one-sided upper confidence limit of mortality rate difference
(SAPIEN - AVR )
Male 25.2% 28.5% 10.7%
Female 29.0% 18.4% -2.4%
![Page 26: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/26.jpg)
26
Primary Endpoint on Different Approaches (ITT)
• Non-significant Interaction (p-value > 0.15)Non-significant Interaction (p-value > 0.15)• Primary Endpoint by Approach
• Nonrandomized Continued Access Protocol CohortNonrandomized Continued Access Protocol Cohort– Transfemoral mortality rate (K-M estimated): 20.6%Transfemoral mortality rate (K-M estimated): 20.6%– 745/1588 (46.9%) transfemoral approach/1588 (46.9%) transfemoral approach
– Transapical mortality rate (K-M estimated): 24.1%Transapical mortality rate (K-M estimated): 24.1%
Approach Control (AVR) SAPIEN (TAVR) 95% one-sided upper confidence limit of mortality rate
difference (SAPIEN - AVR )
Transfemoral 26.4%(n=248)
22.2%(n=244)
2.3%
Transapical 27.9%(n=103)
29.0%(n=104)
11.7%
![Page 27: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/27.jpg)
27
Sponsor Secondary Endpoint: MACCE Sponsor Secondary Endpoint: MACCE (AT)(AT)
• Definition:– Time from randomization to the first occurrence of an
MACCE event (death, MI, all stroke and renal failure) within one year
• KM event rates at 1 year are 26.6% and 27.4% for SAPIEN and AVR respectively for the AT population
• Each of MACCE components are weighted equally
![Page 28: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/28.jpg)
28
Sponsor Secondary Endpoint: Sponsor Secondary Endpoint: Hospitalization (ITT)Hospitalization (ITT)
• Definition– Total Hospital Days Through One Year– Does not count rehabilitation days– Index procedure days are included– Actual number of hospital days used for patients who
died before one year
• Observed– AVR Median: 13 days (range: 0-280)– SAPIEN Median: 10 days (range: 0-187)
![Page 29: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/29.jpg)
29
Secondary Endpoint: NYHA at One Year (ITT)Secondary Endpoint: NYHA at One Year (ITT)• No statistically significant difference at baseline• At 1 Year
– AVR Mean: 1.70 ± 0.76 based on 226/351(64%) patients– SAPIEN Mean: 1.70 ± 0.77 based on 250/348(72%) patients
• Sensitivity analyses regarding missing data conducted• Conclusions indefinite• Difficult to draw firm conclusion due to death & missing data• Possible systematic bias for non-blinded trials
AT population Missing Dead I II III IV Total
AVR 16 77 103 91 21 5 313
SAPIEN 15 80 119 93 32 5 344
![Page 30: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/30.jpg)
30
Sponsor Secondary Endpoint: 6MWT (ITT)Sponsor Secondary Endpoint: 6MWT (ITT)
• Observed – AVR mean (150/351 = 43%): 169.8 ± 134.4 meters– SAPIEN mean (198/348 = 57%): 165.0 ± 128.4
meters• Missing Data Among Alive Patients*
– AVR : 118/268 (44%)– SAPIEN : 71/269 (26%)– *Sponsor calculation:
– AVR: 87/268 (32.5%); SAPIEN: 44/269 (16.4%)• Sensitivity analyses regarding missing data conducted• Conclusions indefinite• Difficult to draw firm conclusion because of missing data
![Page 31: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/31.jpg)
31
30 Day QoL• Observed Measurements
• Sponsor “Predicted” Values
![Page 32: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/32.jpg)
32
SummarySummary
• The study met its pre-specified non-inferiority primary endpoint with a non-inferiority margin of
7.5% on all cause mortality at 1 year.
• Males seemed to perform better with Males seemed to perform better with AVR (Control) • Females seemed to perform better with Females seemed to perform better with SAPIEN
• FDA clinical reviewer will discuss key effectiveness and safety issues
![Page 33: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/33.jpg)
33
FDA Clinical Review of P100041FDA Clinical Review of P100041
Julie A. Swain, MDJulie A. Swain, MDCardiovascular SurgeonCardiovascular Surgeon
Division of Cardiovascular DevicesDivision of Cardiovascular DevicesOffice of Device EvaluationOffice of Device Evaluation
![Page 34: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/34.jpg)
34
SAPIEN Clinical ExperienceSAPIEN Clinical Experience• 11stst US Feasibility US Feasibility• 22ndnd US Feasibility US Feasibility• Roll-in Registry IDE TrialRoll-in Registry IDE Trial
• Randomized, Controlled IDE TrialRandomized, Controlled IDE Trial• Continued Access RegistryContinued Access Registry
• European data 7000+ patientsEuropean data 7000+ patients– EuroScore as inclusion (invalid for isolated valves, over EuroScore as inclusion (invalid for isolated valves, over
predicts mortality 3-7 times)predicts mortality 3-7 times)– Surgeon determination of inoperability or high risk not Surgeon determination of inoperability or high risk not
requiredrequired
![Page 35: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/35.jpg)
35
Patient Selection for TAVR
Operable High Risk Inoperable Inoperable Operable (Benefit (No Benefit to Patient) to Patient)
A?? BB
![Page 36: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/36.jpg)
36
Totality of the DataTotality of the Data
Statistical non-inferiority (mortality: delta 7.5% with actual AVR 27%)
vs.
Judgement of Clinical Equivalence(i.e., substitute for AVR in this population)
![Page 37: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/37.jpg)
37
Primary Safety and Effectiveness EndpointPrimary Safety and Effectiveness Endpoint
Mean F/U time: AVR 1.6 ±1.0 years, TAVR 1.8±1.0 years
![Page 38: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/38.jpg)
38
PARTNERIDE Trial
Cohort A(High Risk Operable)
Open SurgicalIsolated AVR
TranscatheterSAPIEN TAVR
![Page 39: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/39.jpg)
39
0
20
40
60
80
100
Access for TAVR and AVRAVR SAPIEN SAPIEN TF only TF+TA
% Pts
![Page 40: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/40.jpg)
40
Important Considerations
1. Trial conduct Issues2. Neurological damage
3. Aortic Insufficiency
4. Vascular injury/ Bleeding
5. Atrial Fibrillation
![Page 41: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/41.jpg)
41
Trial Conduct Issue:Heterogeneity of Treatment
Control AVR (n= 351)• isolated AVR (222)
• AVR + concomitant operations (40)• No AVR – nothing (38)• Delayed AVR (49)• Unsuccessful AVR (2 [1 TAVR])
SAPIEN (n= 348)• isolated TAVR (<306)
• TAVR – no Rx concomitant (? Assume same)
• No TAVR – nothing (4)• Delayed TAVR (20)• Unsuccessful TAVR (18 [11 AVR])
![Page 42: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/42.jpg)
42
0
5
10
15
AVR SAPIEN
Deteriorate
Withdraw
Refuse
Died
Trial Conduct Issues:No Attempt to Treat
% Pts
n = 5
n = 11
n = 17
n = 5
n = 1
n = 2
![Page 43: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/43.jpg)
43
AVR SAPIEN
Trial Conduct Issue:Failed Treatment (AT)
% Pts
0
5
10
15
N = 2
N = 18
![Page 44: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/44.jpg)
44
AVRto
SAPIEN
SAPIENto
AVR
0
5
10
15
Trial Conduct Issue:Crossover
% Ptsn = 11
n = 1
![Page 45: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/45.jpg)
45
0
5
10
15
AVR SAPIEN
Trial Conduct Issue:Concomitant Operations
% Pts
Not count surgical injury
n = 40
42.5% dead at 1 year
![Page 46: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/46.jpg)
46
Concomitant OperationsCABG 20
CABG + aortic endarterectomy 1
MV repair 4
MV replacement 1
MV repair, annular enlargement 1
MV repair, root enlargement 1
TV repair 1
TV annuloplasty, Root replacement 1
Root/arch replacement 3
Aortoplasty 2
Ascending Aortic endarterectomy 3
Ablation for Atrial Fibrillation 1
Excision Left Atrial Appendage 1
TOTAL Patients with concomitant operations (% total 40/313) (As Treated)
40(12.8%)
• 42.5% (17/40) had died by 1 year
• confounds analysis of adverse events
![Page 47: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/47.jpg)
47
Trial Conduct Issue: Delay between Randomization and Procedure
• Median Delay: AVR 9 days, SAPIEN 7 days • Not Counted in Graph: Pt ID xx030: no AVR because of
“worsening lab values” 14 months after randomization
0
5
10
15
20
% PtsAVR
SAPIEN
![Page 48: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/48.jpg)
48
Trial Conduct Issue:Amount of Missing Data
• 6 MWT Missing Data– AVR : 118/268 (44%)– SAPIEN : 71/269 (26%)
0
10
20
30
40
Pts with AF at Baseline:% missing data at 1 yrfor determination of AF
% Pts
AVR SAPIEN
![Page 49: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/49.jpg)
49
Trial Conduct Issue: Large Variations Among Sites
• Ratio of total screened to enrolled (14% to 63%) [4.5 X] Allocation bias?
• Control Patients not receiving AVR (1% to 20%) [20 X] Treatment/Selection bias?
• Ratio of enrollment in Cohort A to Cohort B (1.0 to 4.1) [4.1 X] Treatment/Selection bias?
• Bleeding complication [3.6 X] Treatment/Assessment bias?
• Variation of missing data between sites (?) and between armsAssessment bias?
![Page 50: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/50.jpg)
50
Primary Safety and Effectiveness EndpointPrimary Safety and Effectiveness Endpoint
Mean F/U time: AVR 1.6 ±1.0 years, TAVR 1.8±1.0 years
![Page 51: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/51.jpg)
51
Important Considerations
1. Trial conduct Issues
2. Neurological damage3. Aortic Insufficiency
4. Vascular injury/ Bleeding
5. Atrial Fibrillation
![Page 52: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/52.jpg)
52
Prespecified Definition of Stroke and TIAPrespecified Definition of Stroke and TIA(CEC Adjudicated)(CEC Adjudicated)
Stroke is a neurological deficit lasting ≥ 24 hours, or lasting < 24 hours with a brain imaging study showing infarction
A transient ischemic attack (TIA) is a fully reversible neurologic event that lasts less than 24 hours and if an imaging study is performed, shows no evidence of infarction.
• DW-MRI Imaging to detect acute infarction rarely done• All SAPIEN TIA’s and 3/5 AVR had a motor deficit• All patients in both arms had general anesthesia
![Page 53: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/53.jpg)
53
Antithrombotic Regimen
Medication Pre-Procedure During Catheterization Post-Procedure 30-Day Follow-up 6 month follow-up
IV Heparin PRN 5000 IU bolus, then as needed to achieve/maintain ACT ≥250 sec
Aspirin 75-100 mg QD 75-100 mg QD 75-100 mg QD 75-100 mg QD
Clopidogrel* 300 mg (if not on long-term therapy)
75 mg QD 75 mg QD 75 mg QD for 6 months
Recommendations for SAPIEN Arm
Recommendations for AVR Arm
Standard of Care at each institution
![Page 54: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/54.jpg)
54
Neurological Events[Miller, et al. J Thorac Cardiovasc Surg 2012;143:832-43]
![Page 55: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/55.jpg)
55
0
25
50
75
100
%Patients
CrossAV(Omran)
Ghanem Kahlert Rodes-Cabau
Astarci Arnold
22
73
84
68
91
68
AVR
(Knipp)
48
AVR
(Astarci)
8
DW-MRI Lesions
![Page 56: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/56.jpg)
56
Cerebral Infarction after TAVI
• ~ 60% scans not done (death, CVA, complications, refusal, etc.)
• Limitations in clinical assessment of stroke, no long-term F/U
• Possible mechanisms of injury: – catheter in arch - crossing stenotic AV– Balloon valvuloplasty - TAVI positioning– TAVI expansion - Corrective manipulation
Future TAVI IDE studies – protocolized neurological assessment by neurologists in at least 50% of patients
![Page 57: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/57.jpg)
57
Transfemoral vs. Transapical: 1 year KM Mortality (AT)
% mortality
0
20
40
AVR SAPIEN
TF TATFTA
![Page 58: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/58.jpg)
58
Transfemoral vs. Transapical: Neurological Events
[Miller, et al. J Thorac Cardiovasc Surg 2012;143:832-43]
![Page 59: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/59.jpg)
59
Important Considerations
1. Trial conduct Issues
2. Neurological damage
3. Aortic Insufficiency4. Vascular injury/ Bleeding
5. Atrial Fibrillation
![Page 60: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/60.jpg)
60
Association Between AR and Mortality
1. Long-term outcomes after transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis: the U.K. TAVI (United Kingdom Transcatheter Aortic Valve Implantation) Registry. Moat NE, et al. J Am Coll Cardiol 2011; 58:2130-2138.
2. Transcatheter aortic valve implantation in patients with severe symptomatic aortic valve stenosis-predictors of mortality and poor treatment response. Gotzmann M, et al. Am Heart J 2011; 162:238.e1-245.e1.
3. Aortic Regurgitation after Transcatheter Aortic Valve Implantation: Incidence and Early Outcome. Results from the German Transcatheter Aortic Valve Interventions Registry.Abdel-Wahab, et al. Heart 2011; 899-906
4. Incidence and Predictors of Early and Late Mortality after Transcatheter Aortic Valve Implantation in 663 Patients with Severe Aortic Stenosis. (Tamburino, et. al, Circulation 2011;123:299-308)
5. Registry of Transcatheter Aortic-Valve Implantation in High-Risk Patients. Gilard M, et al. N Engl J Med 2012;366:1705-1715.
![Page 61: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/61.jpg)
61
Total Aortic RegurgitationTotal Aortic RegurgitationMild (1+) or Greater Mild (1+) or Greater (Central + Paravalvular)(Central + Paravalvular)
0
20
40
60
80
30d 6mos 1yr
% pts
AVR
SAPIEN
![Page 62: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/62.jpg)
62
Total Aortic Regurgitation and Mortality
Kodali, et al. Two-Year Outcomes after Transcatheter or Surgical Aortic-Valve Replacement. NEJM 2012
![Page 63: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/63.jpg)
63
Total AR and Mortality (SAPIEN)
![Page 64: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/64.jpg)
64
Important Considerations
1. Trial conduct Issues
2. Neurological damage
3. Aortic Insufficiency
4. Vascular injury/ Bleeding5. Atrial Fibrillation
![Page 65: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/65.jpg)
65
Vascular Complications
1. Hematoma at access site >5 cm
2. False aneurysm
3. Arterio-venous fistula
4. Retroperitoneal bleeding
5. Peripheral ischemia/nerve injury
6. transfusion for cath complication.
7. Vascular surgical repair **
0
20
40
60
TF TA
% Pts AVR
SAPIEN
![Page 66: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/66.jpg)
66
Vascular Complication in SAPIEN (CEC adjudicated) #events
Myocardial perforation 3
VSD 1
Thoracic aortic dissection 3
Abdominal aortic dissection 1
Iliac or Ileofemoral artery dissection 16
Femoral artery dissection 11
Iliac artery perforation 6
Femoral artery perforation 6
Femoral pseudoaneurysm 6
Iliac or femoral artery embolus 7
Femoral or retroperitoneal hematoma 16
AV fistula 2
Total Events 78
# patients with Vascular Complication 64
Total patients 344
% patients with vascular complication 18.6%
![Page 67: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/67.jpg)
67
Bleeding (<30d)Definition: >3uPRBC or procedure
0
10
20
30
AVR SAPIEN
0
25
50
%Pts
% AVR Pts
Site
• concomitant operations not accounted for• 3.6 fold variation by site• Blood conservation protocols are important (STS guidance)
23%
11%
![Page 68: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/68.jpg)
68
Mortality and Blood Transfusion
Koch CG, et al. Transfusion in Coronary Artery Bypass Grafting is Associated with Reduced Long-Term Survival. Ann Thorac Surg 2006;81:1650-1657
0
2u
3-5u
>6u
“X”u = amount of RBC transfused
![Page 69: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/69.jpg)
69
Important Considerations
1. Trial conduct Issues
2. Neurological damage
3. Aortic Insufficiency
4. Vascular injury/ Bleeding
5. Atrial Fibrillation
![Page 70: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/70.jpg)
70
“New Onset” Atrial Fibrillation
0
5
10
15
20
25
AVR SAPIEN
• Defined as any event >31 seconds• Does not require that patient be treated• Does not count abolishment of AF• Does not consider concomitant operations
% Pts
1.5X difference
![Page 71: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/71.jpg)
71
Presence of Atrial Fibrillation at Followup(FDA Analysis – AT)
0
10
20
30
40
6 mos 1 yr Missingdata 1yr
0
10
20
30
40
6mos 1yr MissingData 1yr
No AF at Baseline:% who developed AF
AF at Baseline:% no AF at Followup
AVR SAPIEN
% Pts% Pts
![Page 72: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/72.jpg)
72
0
10
20
30
13 d
3.6% yr 10 d
2.7% yr
# Days(median)
Total Acute Care Hospital Days to 1 Year
Post Procedure (median)
AVR SAPIENDifference0.8% of year
∆ Percent Hospital Days to 1 Year Post Procedure (median)
OUT
IN
![Page 73: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/73.jpg)
73
Reverse Remodeling(1 yr – baseline)
0
5
10
15
-20
-10
0
-20
-10
0
-40
-30
-20
-10
0
EF %
LVESV ml
LVEDV ml
LV Mass g
AVR SAPIEN
![Page 74: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/74.jpg)
74
Informed Consent• Ensuring true informed consent is important
• Comparison of adverse events needs to be presented.– Death – Neurological events– Vascular complications– Bleeding– Long-term effects of aortic insufficiency– Access incisions
• Panel input: If SAPIEN is approved, how should informed consent be handled?
![Page 75: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/75.jpg)
75
Neuro Events (2X)
Aortic Regurg (4X)
Vascular SAE (3X)
Men?
Proven Durability
Bleeding (2X)
Women ?
Mortality
Atrial Fib
NYHA, QOL, 6MWT
Hosp Days 1 yr
AVR BETTER NO Clinically SAPIEN BETTER Important Difference
AVR vs TAVR in High Risk Operable Patients
![Page 76: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/76.jpg)
76
Summary
• Trial met primary statistical non-inferiority endpoint (mortality non-inferiority delta 7.5%)
• Assessment of Risk/Benefit needs to include consideration of neurological events, aortic insufficiency, vascular complications, gender, and access approach.
• Due to limited clinical data, long term durability still remains in question
![Page 77: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/77.jpg)
77
Post-Approval Study Considerations for
SAPIEN (Cohort A) Transcatheter Heart Valve
Veronica V. Sansing, PhD, MS
Division of Epidemiology
Office of Surveillance and Biometrics / CDRH
June 13, 2012
![Page 78: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/78.jpg)
78
Reminder
• The discussion of a PAS prior to FDA determination of device approvability should not be interpreted to mean FDA is suggesting the device’s safety and effectiveness have been established.
• The plan to conduct a PAS does not decrease the threshold of evidence required by FDA for device approval.
• The premarket IDE data submitted to the Agency and discussed today must stand on its own in demonstrating a reasonable assurance of safety and effectiveness.
![Page 79: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/79.jpg)
79
Need for Post-Approval Studies for PMA
• Gather postmarket information– Long-term performance including effects of re-
treatments & device changes– Broader device performance (patients and clinicians) – Effectiveness of training programs– Sub-group performance
– Outcomes of concern (safety and effectiveness)
• Account for Panel recommendations
![Page 80: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/80.jpg)
80
Post-Approval Study Components
• Fundamental study question or hypothesis
• Safety endpoints and methods of assessment
• Safety & effectiveness endpoints and methods of assessment
• Duration of follow-up
![Page 81: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/81.jpg)
81
Summary of Postmarket Concerns for SAPIEN THV
• Long term device durability
• Long term patient quality of life (QoL)
• Learning curve assessment
• Comparison of
– Postmarket patients with premarket cohort
– Patient populations (gender & race) and outcomes
– Device performance
![Page 82: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/82.jpg)
82
Important Postmarket Concerns for SAPIEN THV
• Long term (5-year) performance– Most IDE patients already have 2-3 years of follow-up data
– Analyses of echo data (durability) & QoL data (yrs. 2-5)
• Learning curve consists of:1) Technical aspects of procedure
• Technical complexity may vary by approach (TA and TF)
2) Appropriate patient selection
![Page 83: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/83.jpg)
83
Important Postmarket Concerns for SAPIEN THV (cont.)
• Performance in gender and minority groups– Gender interaction: Males – Control better, Females – SAPIEN
better
– <10% of IDE patients were minorities, though minorities have poorer outcomes following AVR.1
• Assess valve-in-valve performance– Valve-in-valve implant method rarely seen premarket study
– Reports of this method in literature
[1] Taylor NE, O'Brien S, Edwards FH, Peterson ED, Bridges CR. Relationship between race and mortality and morbidity after valve replacement surgery. Circulation. 2005 Mar 15;111(10):1305-12.
![Page 84: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/84.jpg)
84
Important Postmarket Concerns for SAPIEN THV
• Association between mortality and aortic regurgitation (AR) severity (no/trace vs. mild/moderate/severe) – 1 year: 53% of TAVR pts had mild-severe AR vs.14% AVR
– Increased hazard of mortality for mild-severe AR compared to no/trace AR in TAVR pts (HR – 2.1) premarket
![Page 85: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/85.jpg)
85
Outline for Extended Follow-up of Premarket (PAS 1)
Study Design
Prospective, randomized-controlled, multi-center trial
Objective • Valve implant durability • Long term QoL
Population All IDE patients currently enrolled & alive
• 10-30% of the 699 TAVR pts estimated by year 5
Follow-up Annually through the 2-5 year visits
Endpoints • Durability: Additional analysis of Echocardiogram data– Consented through 5 years
• QoL: KCCQ, EQ5D, SF-12 – Reconsent to collect years 2-5
![Page 86: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/86.jpg)
86
Outline for Newly Enrolled Study (PAS 2)
Study Design Non-randomized prospective, consecutively enrolled registry study
Objectives •Short-term (30-day) and long-term (1-year) safety•Adherence to indications for use/learning curve
1º Endpoint All stroke at 30 days and 1 year
Hypothesis H0: 30-day stroke rate ≥ Comparison rateH1: 30-day stroke rate < Comparison rate
One sided alpha 0.05Population Sites
•High Risk Patients: ≥700 TF & ≥1010 TA•35 sites
Study Design Non-randomized prospective, consecutively enrolled registry study
Objectives •Short-term (30-day) and long-term (1-year) safety•Adherence to indications for use/learning curve
1º Endpoint All stroke at 30 days and 1 year
Hypothesis H0: 30-day stroke rate ≥ Comparison rateH1: 30-day stroke rate < Comparison rate
One sided alpha 0.05Population Sites
•High Risk Patients: ≥700 TF & ≥1010 TA•35 sites
TF TA Pooled
IDE rate x 1.3 margin 14% x 1.3 21% x 1.3 16% x 1.3
Comparison Rate 19% 27% 21%
TF TA Pooled
IDE rate x 1.3 margin 14% x 1.3 21% x 1.3 16% x 1.3
Comparison Rate 19% 27% 21%
![Page 87: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/87.jpg)
87
Outline for Newly Enrolled Study (PAS 2)
Effectiveness- Total days alive and out of hospital - Clinical improvement per NYHA
Class - Mean ICU and total index
procedure hospital length of stay
Follow-up Clinical visits: discharge, 30 days and 1 year (TVT registry)Telephone: annually 2-5 years (CMS linkage)
Additional Endpoints(30 days, 1 year)
Safety
– VARC composite– Major vascular
complications– All neurological events– New permanent
pacemaker– Stroke-free/
rehospitalization-freesurvival
Statistical Kaplan Meier estimate of primary endpoint Additional: Learning curve for VARC composite safety at 30 days
Effectiveness- Total days alive and out of hospital - Clinical improvement per NYHA
Class - Mean ICU and total index
procedure hospital length of stay
Follow-up Clinical visits: discharge, 30 days and 1 year (TVT registry)Telephone: annually 2-5 years (CMS linkage)
Additional Endpoints(30 days, 1 year)
Safety
– VARC composite– Major vascular
complications– All neurological events– New permanent
pacemaker– Stroke-free/
rehospitalization-freesurvival
Statistical Kaplan Meier estimate of primary endpoint Additional: Learning curve for VARC composite safety at 30 days
![Page 88: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/88.jpg)
88
Years 2- 5 CMS Data
• Demographics & clinical status
• Primary Endpoints
• Safety & Effectiveness Outcomes
Year 1TVT Registry
TVT Registry & CMS Data
[1] ISO 5840 Standards for Cardiovascular Implants and Cardiac Valve Prostheses; FDA Draft Guidance for Industry and FDA Staff for Heart Valves; AATS/STS/EACTS Guidelines for Reporting Mortality and Morbidity After Cardiac Valve Interventions
• Link TVT patients to Medicare claims files by direct & indirect patient identifiers.– All claims 1 yr prior to TVT procedure
• Clinically Relevant Endpoints1
• Safety Outcomes & Overall Survival– Annually
![Page 89: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/89.jpg)
89
FDA Assessment of Sponsor’s Proposed PAS
• PAS 1: The follow-up duration of the IDE is 5 years. FDA finds the sponsor’s plans to assess long-term durability and QoL adequate.
PAS 2: The gender*treatment interaction was significant (p<0.10; not powered). FDA recommends that the premarket data be pooled with the postmarket data in order to further analyze the differences by gender.
![Page 90: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/90.jpg)
90
FDA Assessment of Sponsor’s Proposed PAS
PAS 2: Valve-in-valve procedures may occur postmarket. FDA recommends that the PAS be used to monitor short-term and long-term effects of safety and effectiveness of valve-in-valve implantation.
PAS 2: Premarket data showed an increased hazard of mortality in TAVR patients with mild-severe AR compared to those with no-trace AR. The FDA recommends that the PAS include a plan to analyze the association between AR severity and mortality.
![Page 91: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/91.jpg)
91
Summary of FDA ReviewSummary of FDA ReviewP110021P110021
Sonna Patel-Raman, Ph.D.Sonna Patel-Raman, Ph.D.
Circulatory Support and Prosthetics BranchCirculatory Support and Prosthetics BranchDivision of Cardiovascular DevicesDivision of Cardiovascular Devices
Office of Device EvaluationOffice of Device Evaluation
![Page 92: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/92.jpg)
92
Primary EndpointPrimary Endpoint
• Primary endpoint met statistical non-inferiority with 7.5% delta
• Consider additional factors when assessing benefit-risk:– Long-Term Performance and Outcomes– Trial Conduct– Patient Treatment– Neurological Events– Aortic Insufficiency– Vascular Complications
![Page 93: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/93.jpg)
93
Long-Term and Trial ConductLong-Term and Trial Conduct
• Long-term Performance – Valve durability and performance– Patient outcomes
• Trial Conduct– Screening and enrollment– Patient selection– Missing data
![Page 94: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/94.jpg)
94
Patient TreatmentPatient Treatment
• Trial– Open AVR versus Open TAVR?– Concomitant operations– Delay in treatment
• Interpretation of the Data– Males versus Females– Transapical versus Transfemoral
![Page 95: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/95.jpg)
95
SafetySafety
• Neurological adverse events– Higher events in TA– Mitigate risk?
• Aortic Insufficiency– Aortic regurgitation is appreciable at 1-2 years – The long-term clinical significance is unknown
• Vascular complications– 1st generation device/delivery system– Does the training program adequately address
ways to minimize this risk?
![Page 96: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/96.jpg)
96
Additional ConsiderationsAdditional Considerations
• Informed Consent– How much information is enough to convey benefit
versus risk to patients?
• Need for post-approval study– TVT Registry– Determine “real world” use– Interpretation of subjective measures such as
quality of life data in unblinded trials– How long should these patients be followed?
![Page 97: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/97.jpg)
97
Questions?Questions?
![Page 98: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/98.jpg)
98
Back Up Slides
![Page 99: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/99.jpg)
99
Significant Interaction of Treatment*Gender
• Covariates – Treatment, sex, treatment*sex, age, race, BSA,
Diabetes Mellitus (Yes/No), smoking (Yes/No), Arrhythmia (Yes/No), Stroke or TIA within last 6 months (Yes/No), and prior cardiovascular intervention (yes/no), STS score and NYHA
• Logistic Regression – P-value < 0.10
• COX PH Regression – P-value < 0.05
![Page 100: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/100.jpg)
100
30 Day QoL• Observed Measurement s
• Sponsor “Predicted” Values
![Page 101: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/101.jpg)
101
TIAAVR•Garbled speech and altered mental status: (head CT same day, no new infarct)
•Numbness left side of body, blurred vision: (MRI negative)
•Confusion, intermittent confusion, amnesia for morning: (MRI not done (pacer), CT negative)•Right sided weakness and numbness. (No imaging done)
•Aphasia, right sided weakness , persistent dysarthria, 2 days later right sided facial drooping, right sided drooling, garbled speech, expressive aphasia. (Acute CT – no acute findings. No MRI done)
SAPIEN•altered mental status and transient aphasia, delirium, day after TAVR. (Acute CT scan neg for infarct) •2 days after TAVR right sided weakness. (No evidence of imaging)
•Dysarthria, dysphagia (no imaging listed)
•Aphasia, left sided facial droop (No imaging listed)
•Weakness right arm, dysphagia (No imaging listed)
•Loss of sensation and motor power in left upper ext with sudden numbness (No image listed)
![Page 102: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/102.jpg)
102
CMS data & TVT registry
• The TVT registry requirement is for 1 year of follow-up1
– Registry collects all strokes, and does not distinguish between disabling and non-disabling strokes.
• CMS records linked with PAS patient study for 5 year study data– Patients matched on demographics, history of stroke
and heart disease. – However, the sponsor does not account for multiple
CMS records that can serve as a match for one patient.
1. Decision Memo for Transcatheter Aortic Valve Replacement (TAVR) (CAG-00430N)
![Page 103: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/103.jpg)
103
Primary Endpoint (24M, ITT)
![Page 104: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/104.jpg)
104
MACCE (12M, ITT)
![Page 105: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/105.jpg)
105
MACCE (24M, AT)
![Page 106: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/106.jpg)
106
Male(24M, ITT)
![Page 107: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/107.jpg)
107
Female(24M, ITT)
![Page 108: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/108.jpg)
108
TF (24M, ITT)
![Page 109: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/109.jpg)
109
TA(24M, ITT)
![Page 110: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/110.jpg)
110
Death and Missing on 6MWT (Sponsor Claim)
• Sponsor Claim: “Refer to Table 8.4 in Updated Clinical Report, AVR: 87/268 (32.5%), SAPIEN 24/269 (16.4%).”
• Inconsistencies in the sponsor’s calculation: – Number of death (Number of Alive patients)– Missing number among alive patients (Missing due to protocol or
medical reason are NOT counted as “missing”)
![Page 111: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/111.jpg)
111
Death and Missing on 6MWT (FDA Calculation)
– Total: 351 for AVR and 348 for SAPIEN– Death at 1 year: 89 for AVR and 84 for SAPIEN– Observed 6MWT at 1 year: 150 for AVR and 198
for SAPIEN– Missing among alive:
• AVR: (351-89-150)/(351-89) = 112/262=43%• SAPIEN: (348-84-198)/(348-84) = 66/264=25%
![Page 112: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/112.jpg)
112
KCCQ Summary and Physical Limitations
PREDICTIONvs.
OBSERVED
![Page 113: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/113.jpg)
113
KCCQ Total Symptoms, Self-Efficacy, Quality of
Life and Social Limitation
PREDICTIONvs.
OBSERVED
![Page 114: 1 Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and RetroFlex 3 and Ascendra Delivery Systems FDA Review of P110021 Lisa Kennell Division of Cardiovascular.](https://reader036.fdocuments.us/reader036/viewer/2022062314/56649db25503460f94aa1640/html5/thumbnails/114.jpg)
114
SF-12 Physical, SF-12 Mental and EQ-5D Utilities
PREDICTION
vs.OBSERVED